Background: The effect of controlled-onset, extendedrelease (COER) verapamil on haemodynamic parameters in obese and non-obese patients is evaluated in this analysis. Methods: Data were pooled from three clinical trials evaluating efficacy and tolerability of COER-verapamil. Hypertensive men and women (stage I to III) were randomised to COER-verapamil (180-540 mg at bedtime) or placebo for 4 -8 weeks and stratified according to body mass index (BMI-obese Ͼ28 kg/m 2 ). Efficacy was assessed as change from baseline in blood pressure (BP), heart rate, and rate-pressure product during four time periods throughout the dosing interval. Safety and tolerability were assessed by monitoring all adverse